1. Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study
- Author
-
Qin, Kai, Honjo, Kazuhito, Sherrill-Mix, Scott, Liu, Weimin, Stoltz, Regina M., Oman, Allisa K., Hall, Lucinda A., Li, Ran, Sterrett, Sarah, Frederick, Ellen R., Lancaster, Jeffrey R., Narkhede, Mayur, Mehta, Amitkumar, Ogunsile, Foluso J., Patel, Rima B., Ketas, Thomas J., Cruz Portillo, Victor M., Cupo, Albert, Larimer, Benjamin M., Bansal, Anju, Goepfert, Paul A., Hahn, Beatrice H., and Davis, Randall S.
- Subjects
Aged patients -- Care and treatment ,Messenger RNA -- Analysis ,Enzyme-linked immunosorbent assay -- Analysis ,Antigens -- Testing ,Chronic lymphocytic leukemia -- Diagnosis -- Care and treatment ,Biological sciences - Abstract
Background Patients with chronic lymphocytic leukemia (CLL) have reduced seroconversion rates and lower binding antibody (Ab) and neutralizing antibody (NAb) titers than healthy individuals following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA vaccination. Here, we dissected vaccine-mediated humoral and cellular responses to understand the mechanisms underlying CLL-induced immune dysfunction. Methods and findings We performed a prospective observational study in SARS-CoV-2 infection-naïve CLL patients (n = 95) and healthy controls (n = 30) who were vaccinated between December 2020 and June 2021. Sixty-one CLL patients and 27 healthy controls received 2 doses of the Pfizer-BioNTech BNT162b2 vaccine, while 34 CLL patients and 3 healthy controls received 2 doses of the Moderna mRNA-1273 vaccine. The median time to analysis was 38 days (IQR, 27 to 83) for CLL patients and 36 days (IQR, 28 to 57) for healthy controls. Testing plasma samples for SARS-CoV-2 anti-spike and receptor-binding domain Abs by enzyme-linked immunosorbent assay (ELISA), we found that all healthy controls seroconverted to both antigens, while CLL patients had lower response rates (68% and 54%) as well as lower median titers (23-fold and 30-fold; both p 23-fold and >17-fold lower median NAb titers (both p 2.4 mg/L), prior therapy, anti-CD20 immunotherapy ( Conclusions CLL pathogenesis is characterized by a progressive loss of adaptive immune functions, including in most treatment-naïve patients, with preexisting memory being preserved longer than the capacity to mount responses to new antigens. In addition, higher NAb titers and response rates identify mRNA-1273 as a superior vaccine for CLL patients., Author(s): Kai Qin 1, Kazuhito Honjo 1, Scott Sherrill-Mix 2, Weimin Liu 2, Regina M. Stoltz 2, Allisa K. Oman 1, Lucinda A. Hall 3, Ran Li 1, Sarah Sterrett [...]
- Published
- 2023
- Full Text
- View/download PDF